AstraZeneca will present new clinical and real-world data in multiple haematological conditions, further demonstrating its ambition to redefine care in haematology at the European Hematology Association (EHA) 2023 Hybrid Congress, 8 to 11 June 2023.
Acquisition to access global rights to baxdrostat, a novel aldosterone synthase inhibitor in development for blood pressure lowering.
AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.
AstraZeneca and Daiichi Sankyo’s Enhertu also improved progression-free survival by 22 months vs.T-DM1 in patients previously treated with HER2-directed therapy in the DESTINY-Breast03 Phase III trial
Enhertu showed significant progression-free and overall survival improvements vs. chemotherapy in later-line HER2-positive setting in the DESTINY-Breast02 Phase III trial
Updated results fr
Calquence real-world evidence and long-term follow-up data, as well as research collaborations, will reinforce efficacy and safety across B-cell malignancies. Early clinical data will illustrate potential of multiple pipeline molecules, including TNB-486 (AZD0486), across haematologic malignancies. Research from Alexion, AstraZeneca Rare Disease, offers new insights to accelerate innovation and im
Based on DESTINY-Gastric02 which showed AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated clinically meaningful efficacy and DESTINY-Gastric01 which showed improved overall survival compared to chemotherapy.
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adult patients wit
Positive opinion based on TOPAZ-1 Phase III trial updated survival results showing Imfinzi combination reduced risk of death by 24% vs. chemotherapy alone.
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in combination with chemot
First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent in this setting.
AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) for
Additional regulatory milestones demonstrate important progress towards bringing new rare disease medicines to patients in China
AstraZeneca today announced the availability of the first rare disease therapy from Alexion, AstraZeneca’s Rare Disease group, in China. The availability of Soliris (eculizumab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolyti
Approval based on POSEIDON Phase III trial results, which showed significant survival benefit with a limited course of Imjudo added to Imfinzi and chemotherapy.
AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
First and only rescue medication recommended for US approval that has been shown to reduce severe exacerbations.
The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favourable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older. In a
Results presented at American Heart Association (AHA) Scientific Sessions 2022 and being published in the Journal of the American College of Cardiology.
Clinical benefits were observed within two weeks with Farxiga, highlighting the importance of early treatment initiation.
New findings from a pre-specified analysis of DELIVER Phase III trial data show that AstraZeneca’s Farxig
AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
AstraZeneca will present over 60 abstracts across its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio and from Alexion, AstraZeneca’s Rare Disease group, at the American Society of Nephrology (ASN) Kidney Week from 3-6 November 2022 and the American Heart Association (AHA) Scientific Sessions occurring 5-7 November 2022.
Detailed positive results from the Phase III CHAMPION-NMOSD trial showed that Ultomiris (ravulizumab) significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Fasenra demonstrated a statistically significant improvement in histological disease remission, but not a change in dysphagia symptoms, compared to placebo, in patients with EoE aged 12 years or older.
AstraZeneca will showcase new data across its Vaccines and Immune Therapies portfolio at the 11th annual IDWeek conference, 19 – 23 October 2022, reinforcing its commitment to deliver long-lasting immunity for millions of people globally. The Company is set to present seven abstracts at the event.
AstraZeneca has completed the acquisition of TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.1 AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies.
FoCus Phase III trial evaluates new approach to copper mobilisation for patients with Wilson disease who have not seen meaningful innovation in decades. In Wilson disease, excess copper build-up in organs and tissues can lead to liver disease as well as neurological and psychiatric symptoms.
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met its co-primary endpoints in a planned interim analysis at 35 weeks.
AstraZeneca will showcase data demonstrating the Company’s commitment to redefine care in haematology at the European Hematology Association (EHA) Annual Meeting, 9 to 12 June 2022.
AstraZeneca (LSE/STO/Nasdaq: AZN) är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel för sjukdomar inom terapiområdena Onkologi, Sällsynta sjukdomar och Bioläkemedel, inklusive kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar (CVRM) samt Andningsvägar och Immunologi. AstraZeneca är baserat i Cambridge i Storbritannien och bedriver verksamhet i över 100 länder. Dess innovativa läkemedel används av miljontals patienter över hela världen.
Astraallén
151 85 Stockholm